The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer
Open accessAbstract
Breast cancer is the most frequently diagnosed cancer in women and one of the leading causes of cancer death for women. Worldwide, over 1.3 million cases of invasive breast cancer are diagnosed, and more than 450,000 women die from breast cancer annually [1]. In the US, approximately 200,000 cases of invasive breast cancer and 50,000 cases of in situ breast cancer will be diagnosed annually, and more than 40,000 women die from breast cancer each year – second only to lung cancer [2]. The mortality due to breast cancer has been declining in the US since 1990 [2]. The continuing decrease in mortality from breast cancer has been attributed to early detection due to screening, improved adjuvant therapy, and more recently to decreases in the incidence due to lowered rates of usage of hormone replacement therapy [3, 4]. Despite the decreased incidence and mortality, breast cancer remains a major cause of cancer mortality for women and accounts for 15% of all cancer deaths in women in the US [2]. Clinically, breast cancer can be divided into distinct subtypes that have prognostic and therapeutic implications. Breast cancer patients routinely have the expression of estrogen receptor (ER), progesterone receptor (PR), and amplification of HER-2/Neu evaluated [5]. These markers allow classification of breast cancer tumors as hormone receptor positive tumors, HER-2/Neu amplified tumors, and those tumors which do not express ER, PR, and do not have HER-2/Neu amplification. The latter group is referred to as triple-negative breast cancer (TNBC) based on the lack of these three molecular markers. Generally, hormone receptor expressing breast cancers have a more favorable prognosis than either those with HER-2/Neu amplification or those that are triple-negative [5]. While all breast tumor types may be treated with chemotherapy, therapeutic options in both early and late stage breast cancer are affected significantly by the expression of these three markers. Tumors that express ER and PR are treated with agents that interfere with hormone production or action [5]. Tumors that have amplified HER-2/Neu are treated with agents that inhibit HER-2/Neu [5]. These targeted therapies are the mainstay of the successful outcomes seen in hormone receptor positive and HER-2/Neu amplified tumors. Both early stage and advanced TNBC tumors are treated with predominantly chemotherapy [5]. TNBC represents approximately 10–15% of all breast cancers and patients with TNBC have a poor outcome compared to the other subtypes of breast cancer [6]. Interestingly, the incidence of TNBC in African American women is two to three times higher than other ethnic groups, although the reason for this has not been elucidated [6, 7]. Given the lack of validated molecular targets and the poor outcome in patients with TNBC, there is a clear need for a greater understanding of TNBC at all levels and for the development of better therapies. Cancer cell lines have proved useful in laboratory and preclinical investigations since the first cell line was established more than 50 years ago [8]. For example, the anti-HER-2/Neu 4D5 mouse monoclonal antibody (which was humanized to create trastuzumab) had anti-tumor effects as a single agent and acted synergistically with chemotherapeutic agents in breast cancer cell lines that had amplified HER-2/Neu but showed no effect in cell lines lacking amplified HER-2/Neu [9–12]. These results formed the basis for clinical trials of trastuzmab and predicted the outcomes of these clinical trials. Similarly, preclinical studies using xenografts of a hormone receptor expressing breast cancer cell line have accurately predicted the outcomes of clinical trials comparing aromatase inhibitors to tamoxifen and to the combination of tamoxifen and aromatase inhibitors [13]. In this review, we will describe triple negative breast cancer cell lines and discuss their utility and the limitations of these cell lines in the investigation of TNBC (mindful of Harry Callahan’s admonition cited above).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Genes that mediate breast cancer metastasis to the brain
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., et al. (2009) · Nature · doi:10.1038/nature08021 · Cited by 1,863
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Soule, H. D., Maloney, T., Wolman, S. R., Peterson, W., Brenz, R., McGrath, C. M., Russo, J., Pauley, R. J., Jones, R. F., & Brooks, S. C. (1990) · PubMed · Cited by 1,507
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L. L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,139
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Kenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos‐Hoff, M. H., PETERSEN, O. W., et al. (2008) · eScholarship (California Digital Library) · Cited by 1,039
Breast Tumor Cell Lines From Pleural Effusions2
Cailleau, R., Young, R., Olivé, M., & Reeves, W. J. (1974) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/53.3.661 · Cited by 1,015
The Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 982
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES
Scherer, W. F., Syverton, J. T., & Gey, G. O. (1953) · Journal of Experimental Medicine · doi:10.1084/jem.97.5.695 · Cited by 856
Complex landscapes of somatic rearrangement in human breast cancer genomes
Stephens, P. J., McBride, D. J., Lin, M.-L., Varela, I., Pleasance, E. D., Simpson, J. T., Stebbings, L. A., Leroy, C., Edkins, S., Mudie, L. J., et al. (2009) · Nature · doi:10.1038/nature08645 · Cited by 845
Lakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 823
Weaver, V. M., Lelièvre, S., Lakins, J. N., Chrenek, M. A., Jones, J. C. R., Giancotti, F., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 793
Kao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006146 · Cited by 788
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors
Minn, A. J., Kang, Y., Serganova, I. S., Gupta, G. P., Giri, D. D., Doubrovin, M., Ponomarev, V., Gerald, W. L., Blasberg, R. G., & Massagué, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522320 · Cited by 742
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Gene expression profiling of breast cell lines identifies potential new basal markers
Charafe-Jauffret, E., Ginestier, C., Monville, F., Finetti, P., Adélaïde, J., Cervera, N., Fekairi, S., Xerri, L., Jacquemier, J., Birnbaum, D., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209254 · Cited by 569
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 509
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
p53 Mutations in human immortalized epithelial cell lines
Lehman, T. A., Modali, R., Boukamp, P., Stanek, J., Bennett, W. P., Welsh, J. A., Metcalf, R. A., Stampfer, M. R., Fusenig, N., Rogan, E. M., et al. (1993) · Carcinogenesis · doi:10.1093/carcin/14.5.833 · Cited by 447
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Pietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Stampfer, M. R., & Bartley, J. C. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.8.2394 · Cited by 412
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells
Santner, S. J., Dawson, P. J., Tait, L., Soule, H. D., Eliason, J., Mohamed, A. N., Wolman, S. R., Heppner, G. H., & Miller, F. R. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006461422273 · Cited by 408
Multicellular resistance: a paradigm for clinical resistance?
Desoize, B. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00086-x · Cited by 400
TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression
Tang, B., Vu, M., Booker, T., Santner, S. J., Miller, F. R., Anver, M. R., & Wakefield, L. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318899 · Cited by 393
Metformin induces unique biological and molecular responses in triple negative breast cancer cells
Liu, B., Fan, Z., Edgerton, S. M., Deng, X.-S., Alimova, I. N., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8814 · Cited by 392
Mirzoeva, O. K., Das, D., Heiser, L. M., Bhattacharya, S., Siwak, D., Gendelman, R., Bayani, N., Wang, N. J., Neve, R. M., Guan, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3389 · Cited by 385
Rae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R., & Johnson, M. D. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9392-8 · Cited by 374
Bhargava, R., Gerald, W. L., Li, A. R., Pan, Q., Lal, P., Ladanyi, M., & Chen, B. (2005) · Modern Pathology · doi:10.1038/modpathol.3800438 · Cited by 355
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Al-Kuraya, K., Schraml, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1945 · Cited by 347
Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T. W., Lee, F., Shaw, P., & Clark, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3633 · Cited by 344 · cited 2×
“Further study will be necessary to determine if the expression signatures or other molecular markers developed in preclinical studies using the cell lines will allow the identification of a subset of patients in whom dasatinib is efficacious [68, 69].”
BackgroundGazdar, A. F., Kurvari, V., Virmani, A., Gollahon, L., Sakaguchi, M., Westerfield, M., Kodagoda, D., Stasny, V., Cunningham, H. T., Wistuba, I. I., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981209)78:6<766::aid-ijc15>3.0.co;2-l · Cited by 341
Filmus, J., Pollak, M. N., Cailleau, R., & Buick, R. N. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)90131-7 · Cited by 338
Tan, D. S. P., Marchió, C., Jones, R. L., Savage, K., Smith, I. E., Dowsett, M., & Reis-Filho, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9756-8 · Cited by 318
Hackett, A. J., Smith, H. S., Springer, E. L., Owens, R. B., Nelson-Rees, W. A., Riggs, J. L., & Gardner, M. B. (1977) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/58.6.1795 · Cited by 309
Leary, R. J., Lin, J. C., Cummins, J., Boca, S., Wood, L. D., Parsons, D. W., Jones, S., Sjöblom, T., Park, B.-H., Parsons, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808041105 · Cited by 306
BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
Elstrodt, F., Hollestelle, A., Nagel, J. H. A., Gorin, M., Wasielewski, M., van den Ouweland, A., Merajver, S. D., Ethier, S. P., & Schutte, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2853 · Cited by 305
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
Hollestelle, A., Nagel, J. H. A., Smid, M., Lam, S., Elstrodt, F., Wasielewski, M., Ng, S. S., French, P. J., Peeters, J. K., Rozendaal, M. J., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0460-8 · Cited by 301
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Tomlinson, G. E., Chen, T. T., Stastny, V., Virmani, A. K., Spillman, M. A., Tonk, V. S., Blum, J. L., Schneider, N. R., Wistuba, I. I., Shay, J. W., et al. (1998) · PubMed · Cited by 294
Cultivation of Human Breast Carcinomas 2
(1958) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/21.6.1131 · Cited by 276
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer
Weigelt, B., & Bissell, M. J. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.013 · Cited by 273
Seraj, M. J., Samant, R. S., Verderame, M. F., & Welch, D. R. (2000) · PubMed · Cited by 265
Mutations in p53 as potential molecular markers for human breast cancer.
Runnebaum, I. B., Nagarajan, M., Bowman, M., Soto, D., & Sukumar, S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10657 · Cited by 222
MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?
Chambers, A. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1528 · Cited by 218
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Hu, X., Stern, H. M., Ge, L., O'Brien, C., Haydu, L., Honchell, C. D., Haverty, P. M., Peters, B. A., Wu, T. D., Amler, L. C., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0107 · Cited by 217
Targeting the function of the HER2 oncogene in human cancer therapeutics
Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 190
Sartor, C. I., Dziubinski, M. L., Yu, C., Jove, R., & Ethier, S. P. (1997) · PubMed · Cited by 184
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype
Rahman, M., Davis, S. R., Pumphrey, J. G., Bao, J., Nau, M. M., Meltzer, P. S., & Lipkowitz, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9924-5 · Cited by 177
Self-citationBurness, M. L., Grushko, T. A., & Olopade, O. I. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24fc1 · Cited by 176
STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES
Syverton, J. T., & Scherer, W. F. (1952) · Journal of Experimental Medicine · doi:10.1084/jem.96.4.355 · Cited by 167
Further evidence to support the melanocytic origin of MDA-MB-435
Ellison, G. (2002) · Molecular Pathology · doi:10.1136/mp.55.5.294 · Cited by 164
Lineage Infidelity of MDA-MB-435 Cells
Sellappan, S., Grijalva, R., Zhou, X., Yang, W., Eli, M. B., Mills, G. B., & Yu, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3299-2 · Cited by 163
(1980) · PubMed · Cited by 154
Comparison of features of human breast cancer cell lines and their corresponding tumors.
Wistuba, I. I., Behrens, C., Milchgrub, S., Syed, S., Ahmadian, M., Virmani, A. K., Kurvari, V., Cunningham, T. H., Ashfaq, R., Minna, J. D., et al. (1998) · PubMed · Cited by 147
Croix, B. S., Rak, J. W., Kapitain, S. J., Sheehan, C., Graham, C. H., & Kerbel, R. S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.18.1285 · Cited by 107
Characterization of epithelial phenotypes in mortal and immortal human breast cells
Paine, T. M., Soule, H. D., Pauley, R. J., & Dawson, P. J. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910500323 · Cited by 93
Gioanni, J., François, D. L., Zanghellini, E., Mazeau, C., Ettore, F., Lambert, J. C., Schneider, M., & Dutrillaux, B. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.219 · Cited by 91
SUM-159PT cells: a novel estrogen independent human breast cancer model system
Flanagan, L., Weelden, K. V., Ammerman, C., Ethier, S. P., & Welsh, J. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006331716981 · Cited by 86
Young, R. K., Cailleau, R., Mackay, B., & Reeves, W. J. (1974) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02616069 · Cited by 85
Li, Q., Chow, A. B., & Mattingly, R. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.160390 · Cited by 78
Adhesion-dependent multicellular drug resistance.
Green, S. K., Frankel, A. E., & Kerbel, R. S. (1999) · PubMed · Cited by 75
Junk, D. J., Vrba, L., Watts, G. S., Oshiro, M. M., Martinez, J. D., & Futscher, B. W. (2008) · Neoplasia · doi:10.1593/neo.08120 · Cited by 74
Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma properties
Rae, J. M., Ramus, S. J., Waltham, M., Armes, J. E., Campbell, I. G., Clarke, R., Barndt, R. J., Johnson, M. D., & Thompson, E. W. (2004) · Clinical & Experimental Metastasis · doi:10.1007/s10585-004-3759-1 · Cited by 74
Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.
Finn, R., Bengala, C., Ibrahim, N., Strauss, L., Fairchild, J. P., Sy, O., Roche, H. H., Sparano, J. A., & Goldstein, L. J. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-3118 · Cited by 70
Menendez (1992) · International Journal of Oncology · doi:10.3892/ijo_00000106 · Cited by 70
Nicholson, K. M., Streuli, C. H., & Anderson, N. G. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1025765215765 · Cited by 65
Aromatase inhibitor development and hormone therapy: a perspective
Brodie, A. M. H. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00303-8 · Cited by 44
BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers
Yuli, C., Shao, N., Rao, R., Aysola, P., Reddy, V., Oprea-llies, G., Lee, L., Okoli, J., Partridge, E. E., Reddy, E. S. P., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210420 · Cited by 39
Expression of melanocyte-related genes in human breast cancer and its implications
Montel, V., Suzuki, M., Galloy, C., Mose, E. S., & Tarin, D. (2009) · Differentiation · doi:10.1016/j.diff.2009.07.007 · Cited by 35
Even Better Kinase Inhibitors for Chronic Myeloid Leukemia
Sawyers, C. L. (2010) · New England Journal of Medicine · doi:10.1056/nejme1004430 · Cited by 30
Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients
Wong, J., Augero, B., Gupta, R., & Morton, D. (1988) · Cancer Immunology Immunotherapy · doi:10.1007/bf00200019 · Cited by 14
Cited by
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 368
Bourgeois-Daigneault, M.-C., Roy, D. G., Aitken, A. S., El Sayes, N., Martin, N. T., Varette, O., Falls, T., St-Germain, L. E., Pelin, A., Lichty, B. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao1641 · Cited by 293
Breast tumours maintain a reservoir of subclonal diversity during expansion
Minussi, D. C., Nicholson, M. D., Ye, H., Davis, A., Wang, K., Baker, T., Tarabichi, M., Sei, E., Du, H., Rabbani, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03357-x · Cited by 256
Hybrid Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Modulating Tumor Hypoxia
Abbasi, A. Z., Gordijo, C. R., Amini, M. A., Maeda, A., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3475 · Cited by 121
Cuesta, R., & Holz, M. K. (2016) · Oncotarget · doi:10.18632/oncotarget.8375 · Cited by 37
Metadata
- Authors
- Chavez, K. J., Garimella, S. V., & Lipkowitz, S.
- Venue
- Breast Disease
- Publisher
- SAGE Publications
- Published
- 2011-03-15
- Volume
- 32
- Issue
- 1-2
- Pages
- 35-48
- ISSN
- 0888-6008 (ISSN-L)
- 1558-1551
- OpenAlex
- W1555009525
- Cited by
- 762
- References
- 91
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.